The treatment of uremia mainly relies on dialysis, but existing methods yield unsatisfactory outcomes, prompting the investigation of new biomarkers.*
-
Researchers focused on the role of DNA 5-hydroxymethylcytosine (5-hmC) by comparing its levels in uremic patients versus healthy controls, using modern genomic techniques.*
-
The study identified significant differences in 5-hmC levels across many genes in uremia patients, suggesting potential for 5-hmC as a biomarker or therapeutic target in treating uremia.*